Health Products

ENGAGER TRANSCATHETER AORTIC BIOPROSTHESIS (2015-07-03)

· Published by Health Canada · Official notice

Details

Alert type: Medical Device Recall
Category: Medical Device
Issue: Medical Devices
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type II
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

Lot or serial numberCompaniesBrand nameModel or catalog number
All lots
Manufacturer
Medtronic 3F Therapeutics Inc
1851 East Deere Ave.
Santa Ana
92705
UNITED STATES
A. ENGAGER TRANSCATHETER AORTIC BIOPROSTHESISME-TA2-B23

Introduction

Affected Products

A. ENGAGER TRANSCATHETER AORTIC BIOPROSTHESIS

Reason

A review of the 2-year follow-up data of engager European pivotal trial has shown that 16 of 32 subjects implanted with a 23mm device have a mean gradient of = 20 MMHG at some point after the implant (average mean gradient at 2-year follow up: 22.0 ? 7.5 MMHG). Gradient is a measure of the resistance to flow through the valve. A mean gradient of 20-40 MMHG is associated with mild stenosis (narrowing of the valve) per the valve academic research consortium (VARC) -2 guideline.  No interventions, balloon valvuloplasty, or surgical replacement were performed related to the elevated gradient on the 16 study patients. As a result of these data, Medtronic has made the decision to voluntarily discontinue sales and distribution of the 23mm Bioprosthesis permanently. This recall affects only the 23mm Engager Bioprosthesis.
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime